Cyclerion Therapeutics
CYCN
40 hedge funds and large institutions have $13.7M invested in Cyclerion Therapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
15,250% more call options, than puts
Call options by funds: $307K | Put options by funds: $2K
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more funds holding
Funds holding: 37 → 40 (+3)
0.05% less ownership
Funds ownership: 2.44% → 2.39% (-0.05%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
25% less capital invested
Capital invested by funds: $18.3M → $13.7M (-$4.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$28.7K |
| 2 |
Jane Street
New York
|
+$15.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.45K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$210K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$80K |
| 3 |
Renaissance Technologies
New York
|
-$59K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$17K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$17K |
CYCN Hedge Fund Activity: Q4 2022 in Review
40 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q4 2022, worth a combined $13.7M — down 25% from $18.3M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CYCN positions and 5 closed out — a net gain of 3 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $28.7K. The largest seller was Diametric Capital, exiting entirely with an estimated $210K sold.
- 40 institutional investors held Cyclerion Therapeutics (CYCN) as of Q4 2022, up from 37 in Q3 2022.
- Funds reported $13.7M of Cyclerion Therapeutics stock for Q4 2022, down 25% quarter-over-quarter.
- 8 funds opened new Cyclerion Therapeutics positions in Q4 2022 and 5 closed out, a net change of +3 holders.
- The largest Cyclerion Therapeutics buyer in Q4 2022 was Virtu Financial, an estimated $28.7K added.
- The largest Cyclerion Therapeutics seller in Q4 2022 was Diametric Capital, an estimated $210K sold.
Based on aggregated 13F filings for Q4 2022.